Company / Operating Cash Flow
GT Biopharma, Inc. Operating Cash Flow History
FY2011-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$3.7M
FY2020
5-year range
-$4.7M / -$442.0K
FY2016-FY2020
Trend
-89.6%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 8 years, ranging from -$5M in FY2016 to -$442,000 in FY2014.
Based on SEC 10-K filings.
-$4M in FY2020.
Improved from -$5M to -$4M over the past 4 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, operating cash flow decreased 89.6% year-over-year.
- Peak operating cash flow was recorded in FY2014.
- Lowest operating cash flow in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | -$3.7M | -89.6% |
| FY2017 | -$1.9M | +58.6% |
| FY2016 | -$4.7M | -166.3% |
| FY2015 | -$1.7M | -295.7% |
| FY2014 | -$442.0K | +55.2% |
| FY2013 | -$987.0K | -2.5% |
| FY2012 | -$963.0K | +37.3% |
| FY2011 | -$1.5M | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026